Glioma
📧 Sign up to get email alerts when something new happens for Glioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors [Phase 1, Phase 2]
Clinical trial updates the evaluation of an IDO inhibitor in combination with temozolomide for adult malignant brain tumors, including gliob…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma [Phase 3]
A Phase 3 clinical trial evaluating electroacupuncture combined with paclitaxel for recurrent high-grade glioma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: Fluorescence-guided Surgery for Low- and High-grade Gliomas [Phase 3]
Phase 3 clinical trial evaluating fluorescence-guided surgery for gliomas has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma [Phase 2]
Phase 2 trial evaluating a Protein Phosphatase 2A inhibitor in recurrent glioblastoma and related gliomas completed, with results posted in …
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma [Phase 2]
Phase 2 trial updating safety and efficacy of TVI-Brain-1 for recurrent grade IV glioma; results posted after completion.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma [Phase 1, Phase 2]
A Phase I/II trial evaluating TVI-Brain-1 for safety and efficacy in recurrent high-grade gliomas, including glioblastoma multiforme, has co…
-
CLINICAL_TRIALS research · 2023-06-01Clinical Trial Update: nTMS for Motor Mapping of Rolandic Lesions [Phase 2, Phase 3]
Clinical trial update on navigated transcranial magnetic stimulation (nTMS) for motor mapping in Rolandic region lesions, with Phase 2 and P…
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 Pediatric MATCH trial evaluating Ulixertinib for MAPK-pathway-mutant tumors in children, including advanced solid tumors, Non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2023-05-01Clinical Trial Update: Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy [Phase 2, Phase 3]
Clinical trial update for postoperative radiotherapy in glioma patients assessing neuropsychological and oncological outcomes; currently rec…
-
EMA withdrawal · 2023-03-06EMA Withdrawn: Temozolomide Sandoz (temozolomide) — Sandoz GmbH
EMA withdrew Temozolomide Sandoz (temozolomide) from the market; therapeutic area Glioma.
-
EMA withdrawal · 2023-02-27EMA Withdrawn: Temozolomide Hexal (temozolomide) — Hexal AG
Temozolomide Hexal has been withdrawn from the market by Hexal AG in Europe for glioma.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2A study update for LAM561 in adults with advanced solid tumours has completed enrollment.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [Phase 1, Phase 2]
Phase 1/2 trial evaluating FT-2102 in IDH1-mutant advanced solid tumors and gliomas; study completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma [Phase 1]
Phase 1 trial update of neural stem cell–based virotherapy for newly diagnosed malignant glioma; study completed with results posted in 2023…
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence [Phase 2]
Phase 2 trial comparing low-dose bevacizumab with hypofractionated stereotactic radiotherapy versus bevacizumab alone for recurrent glioblas…
-
CLINICAL_TRIALS trial_result · 2022-10-06Clinical Trial Update: 68Ga-P16-093 PET/CT Imaging in Glioma Patients [Phase 1, Phase 2]
Clinical trial update on 68Ga-P16-093 PET/CT imaging in glioma patients across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations [Phase 2]
Phase 2 trial evaluating dasatinib with everolimus in pediatric and young adult gliomas with PDGFR alterations was terminated with posted re…
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma [Phase 2]
Phase 2 trial evaluating 18F-DOPA-PET utility in treating recurrent high-grade glioma completed with posted results.
-
EMA withdrawal · 2022-06-17EMA Application withdrawn: Sitoiganap (allogeneic glioma tumor cell lysates (inactivated);allogeneic glioma tumor cells (inactivated);autologous glioma tumor cell lysates (inactivated);autologous glioma tumor cells (inactivated)) — Epitopoietic Research Corporation-Belgium (E.R.C.)
The EMA has withdrawn the application for Sitoiganap, an immunotherapy consisting of inactivated allogeneic/autologous glioma tumor cell lys…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer [Phase 3]
A Phase 3 clinical trial update for DCVax-L in newly diagnosed glioblastoma multiforme is reported with unknown current status.
-
EMA approval · 2022-03-28EMA Authorised: Temomedac (temozolomide) — medac Gesellschaft für klinische Spezialpräparate mbH
Temomedac (temozolomide) has been authorised in Europe for glioma by medac, with decision date 25/03/2022.
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Seizure Prophylaxis in Patients With Glioma or Brain Metastasis [Phase 2]
Phase 2 trial update on seizure prophylaxis in patients with glioma or brain metastasis; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: iMRI Guided Resection in Cerebral Glioma Surgery [Phase 3]
Phase 3 clinical trial evaluating iMRI-guided resection in cerebral glioma surgery has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas [Phase 2]
Phase 2 trial evaluating selinexor (KPT-330) in recurrent gliomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects [Phase 2]
Phase 2 trial evaluating combination of an oncolytic adenovirus with pembrolizumab for brain cancers has completed.